--- title: "City Therapeutics hits 52-week low" type: "News" locale: "en" url: "https://longbridge.com/en/news/304474029.md" description: "City Therapeutics fell 1.65% to US$16.14. Down 26.47% over five sessions and down 9.56% from IPO price." datetime: "2026-11-05T14:31:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304474029.md) - [en](https://longbridge.com/en/news/304474029.md) - [zh-HK](https://longbridge.com/zh-HK/news/304474029.md) generator: "portal-rs" --- # City Therapeutics hits 52-week low City Therapeutics (CTY.US) slipped nearly **2%** during regular trading to **$16.14**, hitting a 52-week low intraday. The stock is down 26.47% over the past five sessions and down 9.56% from its IPO price. It sits 32.41% below its 52-week high of US$23.88. The Nasdaq Composite is down 2.65% over the past five sessions and up 9.68% year to date. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [CTY.US](https://longbridge.com/en/quote/CTY.US.md) ## Related News & Research - [Space Exploration Technologies (SPCX) Gets A New Hiring Twist As Musk Eyes Top AI Talent](https://longbridge.com/en/news/306383945.md) - [Salesforce (CRM) Chosen To Lead U.S. Backed Super Intelligence Export Group](https://longbridge.com/en/news/306383121.md) - [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md) - [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md) - [MOG.A: FY27 guidance targets 9% sales growth and a 14.2% adjusted segment margin](https://longbridge.com/en/news/306365896.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**